ストックスクリーナーアプリを入手
0.8297
2.42%
0.0196
前日終値:
$0.8101
開ける：
$0.8337
24時間の取引高:
3.29M
Relative Volume:
1.13
時価総額：
$324.80M
収益：
$86.26M
当期純損益:
$-50.08M
株価収益率:
-3.3879
EPS:
-0.2449
ネットキャッシュフロー:
$-94.48M
1週間 パフォーマンス:
-8.51%
1か月 パフォーマンス:
-16.12%
6か月 パフォーマンス:
-50.02%
1年 パフォーマンス:
-23.88%
1日の値動き範囲:
$0.7976
$0.8419
1週間の範囲:
$0.7976
$0.9292
52週間の値動き範囲:
$0.79
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Compare LAB vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.8297 | 324.80M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-13 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-02-27 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | 開始されました | TD Cowen | Buy |
| 2024-04-04 | 開始されました | Jefferies | Buy |
| 2023-07-12 | 開始されました | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc (LAB) 最新ニュース
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB - The Malone Telegram
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AstroNova, Inc. (Nasdaq – ALOT), Open Lending Corporation (Nasdaq – LPRO), Huntsman Corporation (NYSE – HUN), Standard BioTools Inc. (Nasdaq – LAB) - GlobeNewswire Inc.
Standard BioTools Shareholders Approve 2026 Equity Incentive Plans - TipRanks
Standard BioTools (LAB) investors approve 2026 equity plan and ESPP share increase - Stock Titan
Standard BioTools Inc (LAB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Standard BioTools Inc (LAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Standard BioTools Inc (LAB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Standard BioTools Inc (LAB) Institutional Confidence - TradingKey
Standard BioTools Inc (LAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Standard BioTools Inc (LAB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Standard BioTools Inc (LAB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Standard BioTools Inc (LAB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Standard BioTools Inc (LAB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Standard BioTools (LAB) Slides 3.65% as Biotech Sector Faces HeadwindsNAAIM Leverage - newsline.com
Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders? - TradingView
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Viking backs Standard BioTools (LAB) merger with Treeline Biosciences - Stock Titan
Casdin funds deepen tie to Standard BioTools (LAB) with 23.9% stake and Treeline merger support - Stock Titan
Company that shut down Peninsula HQ now swept up in reverse merger - The Business Journals
Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings - Sahm
Stealthy startup Treeline plans a reverse merger - BioPharma Dive
Standard BioTools to merge with Treeline in biotech transformation deal - The Pharma Letter
Standard BioTools Inc. (LAB) Discusses Merger and Strategic RationaleSlideshow (NASDAQ:LAB) 2026-06-08 - Seeking Alpha
Standard BioTools (LAB) Plunges Over 30%, Testing Critical Support at $0.76PCR Spike - newsline.com
Standard BioTools and Treeline Biosciences anno... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Standard BioTools and Treeline Biosciences Announce $900M Merger to Form Public Biopharma Company Focused on Oncology and Precision Medicines 12 - Minichart
Standard BioTools to Merge with Treeline Biosciences - TipRanks
Standard BioTools (NASDAQ: LAB) to merge with Treeline in $2.5B exchange‑ratio deal - Stock Titan
Standard BioTools to Merge With Treeline in All-Stock Deal Valuing Treeline at $2.5 Billion - TradingView
Treeline Biosciences, Standard BioTools (NASDAQ: LAB) plan all-stock merger - Stock Titan
Standard BioTools and Treeline Biosciences Agree to Merger, Creating Well-Funded Clinical-Stage Biopharma Company - citybiz
Standard BioTools, Treeline Biosciences to Merge in All-Stock Deal - marketscreener.com
Standard BioTools to merge with Treeline Biosciences By Investing.com - Investing.com Nigeria
Standard BioTools to merge with Treeline Biosciences - Investing.com
$900M cancer drug pipeline: Treeline, Standard BioTools to merge - Stock Titan
Standard BioTools Regains Compliance With Nasdaq's Minimum Bid Price Requirement - marketscreener.com
Fenwick Represents Treeline Biosciences in Definitive Merger Agreement with Standard BioTools - fenwick.com
Standard BioTools Inc. 8-K Filing Details for June 5, 2026: Company Information, NASDAQ Listing, and Legal Disclosures – Minichart - Minichart
Standard BioTools Regains Nasdaq Minimum Bid Compliance Status - TipRanks
Standard BioTools regains Nasdaq bid-price compliance; matter closed - TradingView
Standard BioTools (NASDAQ: LAB) back in compliance with Nasdaq bid rule - Stock Titan
Standard BioTools Grants RSUs to Chief Business Officer - TipRanks
Standard BioTools (LAB) awards 500,000 RSUs to Chief Business Officer - Stock Titan
Standard BioTools Adopts New Executive Severance Protection Plans - TipRanks
Standard BioToolsapproves 2026 change of control and severance plan on May 21, 2026 - marketscreener.com
Standard BiotoolsApproves 2026 Change Of Control And Severance Plan On May 21, 2026 - TradingView
Standard BioTools CFO Alex Kim and CBO Sean Mackay enter 2026 Severance Plan; CEO Michael Egholm joins 2023 Plan - TradingView
Standard BioTools (LAB) sets new executive and CEO change-of-control severance terms - Stock Titan
Standard Biotools Live Share Prices and Trades. LAB.US Live Streaming Share Prices. - London South East
Standard BioTools shares hold over $1 as Nasdaq deadline nears - Bez Kabli
Standard BioTools (LAB) Hovers Near Support After Modest DeclineBlue Chip Entry Points - The Legal Advocate
Standard Biotools Inc (LAB) 財務データ
収益
当期純利益
現金流量
EPS
0.93%
大文字化:
|
ボリューム (24 時間):